What question did this study set out to answer?

To investigate the impact of anti-GM3 IgG antibodies on the presentation and treatment of Guillain–Barré syndrome.

January 16, 2026Science Progress0 citationsOpen Access

Guillain–Barré syndrome with unilateral oculomotor nerve palsy and anti-GM3 IgG antibodies

MXMinjia XiaoShanghai University of Traditional Chinese Medicine XHXiang HuangShanghai University of Traditional Chinese Medicine

Key Points

To investigate the impact of anti-GM3 IgG antibodies on the presentation and treatment of Guillain–Barré syndrome.
Case report of a male in his 70s with GBS and anti-GM3 IgG antibodies
IVIG therapy administered for treatment
Follow-up assessments conducted at six months to evaluate symptom resolution
Unilateral oculomotor nerve palsy developed during IVIG therapy
Complete remission of symptoms confirmed at six-month follow-up
Demonstrated therapeutic value of IVIG in complicated cases of GBS

Abstract

Guillain–Barré syndrome (GBS) is a life-threatening acute paralytic neuropathy characterized by rapidly progressive limb weakness and bilateral cranial nerve involvement. We report an early 70s male with no relevant medical history diagnosed with anti-GM3 IgG-positive GBS, who developed unilateral oculomotor nerve palsy and autonomic dysfunction during intravenous immunoglobulin (IVIG) therapy, with spontaneous symptom resolution following IVIG completion. Six-month follow-up assessments confirmed complete remission. This case reinforces the therapeutic value of IVIG in GBS patients with specific autoantibody profiles, even when complicated by transient neurological deterioration during treatment.

问 AI

Bookmark

View Full Paper